OM:HNSABiotechs
Hansa Biopharma (OM:HNSA) Heavy SEK 529 Million TTM Losses Test Bullish Turnaround Narrative
Hansa Biopharma (OM:HNSA) has reported full year 2025 results with fourth quarter revenue of SEK 76.0 million and a basic EPS loss of SEK 1.62, alongside a trailing twelve month EPS loss of SEK 6.52 on revenue of SEK 222.3 million. The company has seen quarterly revenue move between SEK 30.8 million and SEK 76.0 million across 2025, while quarterly basic EPS stayed in loss-making territory, ranging from SEK 0.55 to SEK 2.53 per share. For investors, the latest print keeps the focus squarely...